Benchmark Upgrades AbCellera Biologics to Buy, Announces $11 Price Target

Benzinga Newsdesk www.benzinga.com Positive 74.0%

Neg 0% Neu 0% Pos 74%

Benchmark analyst Robert Wasserman upgrades AbCellera Biologics (NASDAQ:ABCL) from Hold to Buy and announces $11 price target.